Astellas

News

The EMA has started a review of a regimen based on Pfizer/Astellas' Padcev and MSD's Keytruda that is described as a game-changer for bladder cancer.

Oncology

At ESMO 2025 in Berlin, pharmaphorum spoke with Tadaaki Taniguchi, Chief Research & Development Officer at Astellas.

News

Astellas' effort to expand the reach of its first-in-class claudin 18.2 drug Vyloy into pancreatic cancer has had a major setback.

News

A survey of women across six countries has found more than a third have experienced some kind of negative impact in the workplace due to menopause.

News

A new treatment regimen for advanced bladder cancer combining MSD's Keytruda with Astellas' Padcev has been given the green light for NHS use.

News

Astellas and Pfizer plan to file Padcev for earlier-stage bladder cancer after showing a survival benefit in a combination regimen with Keytruda.